Skip to main content
Erschienen in: Tumor Biology 10/2015

01.10.2015 | Research Article

RNA interference against TMEM97 inhibits cell proliferation, migration, and invasion in glioma cells

verfasst von: Guanzhong Qiu, Wei Sun, Yongxiang Zou, Zheng Cai, Peng Wang, Xianbin Lin, Jinxiang Huang, Lei Jiang, Xuehua Ding, Guohan Hu

Erschienen in: Tumor Biology | Ausgabe 10/2015

Einloggen, um Zugang zu erhalten

Abstract

Gliomas are the most common form of primary brain tumor in the adult central nervous system. Altered expression and prognostic value of transmembrane protein 97 (TMEM97) has been recently reported in different types of human tumors. However, the association of TMEM97and glioma is poorly defined. Here, we reported that TMEM97 was significantly increased in glioma tissues compared to non-tumorous brain tissues. Furthermore, TMEM97 levels were progressively increased with increasing histologic tumor grade in glioma. Higher TMEM97 expression level was correlated with shorter survival time of patients with glioma. Downregulation of TMEM97 through RNA interference inhibited cell proliferation and G1/S transition in two glioma cell lines, U87 and U373. More importantly, TMEM97 silencing induced a significant decrease in the expression of G1/S transition key regulators, cyclin D1, cyclin E, CDK2, and CDK4. Additionally, downregulation of TMEM97 in glioma cells notably repressed cell migration and cell invasion. Further analysis suggested that the decreased invasion was associated with alterations in EMT markers, including E-cadherin, β-catenin, and Twist. Since expression of TMEM97 seems to be associated with the oncogenic potential of glioma, and suppression of its expression can inhibit cancer cell growth and metastasis, TMEM97 may be a potential therapeutic target in human glioma.
Literatur
1.
Zurück zum Zitat Sathornsumetee S, Rich JN. New treatment strategies for malignant gliomas. Expert Rev Anticancer Ther. 2006;6(7):1087–104.CrossRefPubMed Sathornsumetee S, Rich JN. New treatment strategies for malignant gliomas. Expert Rev Anticancer Ther. 2006;6(7):1087–104.CrossRefPubMed
2.
Zurück zum Zitat Davis FG, Freels S, Grutsch J, Barlas S, Brem S. Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on surveillance, epidemiology, and end results (SEER) data, 1973–1991. J Neurosurg. 1998;88(1):1–10.CrossRefPubMed Davis FG, Freels S, Grutsch J, Barlas S, Brem S. Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on surveillance, epidemiology, and end results (SEER) data, 1973–1991. J Neurosurg. 1998;88(1):1–10.CrossRefPubMed
3.
Zurück zum Zitat Penas-Prado M, Gilbert MR. Molecularly targeted therapies for malignant gliomas: advances and challenges. Expert Rev Anticancer Ther. 2007;7(5):641–61.CrossRefPubMed Penas-Prado M, Gilbert MR. Molecularly targeted therapies for malignant gliomas: advances and challenges. Expert Rev Anticancer Ther. 2007;7(5):641–61.CrossRefPubMed
4.
Zurück zum Zitat Murphy M, Pykett MJ, Harnish P, Zang KD, George DL. Identification and characterization of genes differentially expressed in meningiomas. Cell Growth Differ: Mol Biol J Am Assoc Cancer Res. 1993;4(9):715–22. Murphy M, Pykett MJ, Harnish P, Zang KD, George DL. Identification and characterization of genes differentially expressed in meningiomas. Cell Growth Differ: Mol Biol J Am Assoc Cancer Res. 1993;4(9):715–22.
5.
Zurück zum Zitat Malhotra K, Luehrsen KR, Costello LL, et al. Identification of differentially expressed mRNAs in human fetal liver across gestation. Nucleic Acids Res. 1999;27(3):839–47.CrossRefPubMedPubMedCentral Malhotra K, Luehrsen KR, Costello LL, et al. Identification of differentially expressed mRNAs in human fetal liver across gestation. Nucleic Acids Res. 1999;27(3):839–47.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Bartz F, Kern L, Erz D, et al. Identification of cholesterol-regulating genes by targeted RNAi screening. Cell Metab. 2009;10(1):63–75.CrossRefPubMed Bartz F, Kern L, Erz D, et al. Identification of cholesterol-regulating genes by targeted RNAi screening. Cell Metab. 2009;10(1):63–75.CrossRefPubMed
7.
Zurück zum Zitat Wilcox CB, Feddes GO, Willett-Brozick JE, Hsu LC, DeLoia JA, Baysal BE. Coordinate up-regulation of TMEM97 and cholesterol biosynthesis genes in normal ovarian surface epithelial cells treated with progesterone: implications for pathogenesis of ovarian cancer. BMC Cancer. 2007;7:223.CrossRefPubMedPubMedCentral Wilcox CB, Feddes GO, Willett-Brozick JE, Hsu LC, DeLoia JA, Baysal BE. Coordinate up-regulation of TMEM97 and cholesterol biosynthesis genes in normal ovarian surface epithelial cells treated with progesterone: implications for pathogenesis of ovarian cancer. BMC Cancer. 2007;7:223.CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Kayed H, Kleeff J, Ding J, et al. Expression analysis of MAC30 in human pancreatic cancer and tumors of the gastrointestinal tract. Histol Histopathol. 2004;19(4):1021–31.PubMed Kayed H, Kleeff J, Ding J, et al. Expression analysis of MAC30 in human pancreatic cancer and tumors of the gastrointestinal tract. Histol Histopathol. 2004;19(4):1021–31.PubMed
9.
Zurück zum Zitat Moparthi SB, Arbman G, Wallin A, et al. Expression of MAC30 protein is related to survival and biological variables in primary and metastatic colorectal cancers. Int J Oncol. 2007;30(1):91–5.PubMed Moparthi SB, Arbman G, Wallin A, et al. Expression of MAC30 protein is related to survival and biological variables in primary and metastatic colorectal cancers. Int J Oncol. 2007;30(1):91–5.PubMed
10.
Zurück zum Zitat Yan BY, Wang DW, Zhu ZL, et al. Overexpression of MAC30 in the cytoplasm of oral squamous cell carcinoma predicts nodal metastasis and poor differentiation. Chemotherapy. 2010;56(6):424–8.CrossRefPubMed Yan BY, Wang DW, Zhu ZL, et al. Overexpression of MAC30 in the cytoplasm of oral squamous cell carcinoma predicts nodal metastasis and poor differentiation. Chemotherapy. 2010;56(6):424–8.CrossRefPubMed
11.
Zurück zum Zitat Zhao ZR, Zhang LJ, He XQ, et al. Significance of mRNA and protein expression of MAC30 in progression of colorectal cancer. Chemotherapy. 2011;57(5):394–401.CrossRefPubMed Zhao ZR, Zhang LJ, He XQ, et al. Significance of mRNA and protein expression of MAC30 in progression of colorectal cancer. Chemotherapy. 2011;57(5):394–401.CrossRefPubMed
12.
Zurück zum Zitat Xiao M, Li H, Yang S, et al. Expression of MAC30 protein is related to survival and clinicopathological variables in breast cancer. J Surg Oncol. 2013;107(5):456–62.CrossRefPubMed Xiao M, Li H, Yang S, et al. Expression of MAC30 protein is related to survival and clinicopathological variables in breast cancer. J Surg Oncol. 2013;107(5):456–62.CrossRefPubMed
13.
Zurück zum Zitat Han KY, Gu X, Wang HR, Liu D, Lv FZ, Li JN. Overexpression of MAC30 is associated with poor clinical outcome in human non-small-cell lung cancer. Tumour Biol: J Int Soc Oncodevelop Biol Med. 2013;34(2):821–5.CrossRef Han KY, Gu X, Wang HR, Liu D, Lv FZ, Li JN. Overexpression of MAC30 is associated with poor clinical outcome in human non-small-cell lung cancer. Tumour Biol: J Int Soc Oncodevelop Biol Med. 2013;34(2):821–5.CrossRef
14.
Zurück zum Zitat Yang S, Li H, Liu Y, et al. Elevated expression of MAC30 predicts lymph node metastasis and unfavorable prognosis in patients with epithelial ovarian cancer. Med Oncol (Northwood, London, England). 2013;30(1):324.CrossRef Yang S, Li H, Liu Y, et al. Elevated expression of MAC30 predicts lymph node metastasis and unfavorable prognosis in patients with epithelial ovarian cancer. Med Oncol (Northwood, London, England). 2013;30(1):324.CrossRef
15.
Zurück zum Zitat Papavasiliou FN, Schatz DG. Cell-cycle-regulated DNA double-strand breaks in somatic hypermutation of immunoglobulin genes. Nature. 2000;408(6809):216–21.CrossRefPubMed Papavasiliou FN, Schatz DG. Cell-cycle-regulated DNA double-strand breaks in somatic hypermutation of immunoglobulin genes. Nature. 2000;408(6809):216–21.CrossRefPubMed
16.
Zurück zum Zitat Thiery JP. Epithelial–mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002;2(6):442–54.CrossRefPubMed Thiery JP. Epithelial–mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002;2(6):442–54.CrossRefPubMed
17.
Zurück zum Zitat Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009;9(3):153–66.CrossRefPubMed Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009;9(3):153–66.CrossRefPubMed
18.
Zurück zum Zitat Nakada M, Nakada S, Demuth T, Tran NL, Hoelzinger DB, Berens ME. Molecular targets of glioma invasion. Cell Mol Life Sci: CMLS. 2007;64(4):458–78.CrossRefPubMed Nakada M, Nakada S, Demuth T, Tran NL, Hoelzinger DB, Berens ME. Molecular targets of glioma invasion. Cell Mol Life Sci: CMLS. 2007;64(4):458–78.CrossRefPubMed
19.
Zurück zum Zitat Schmalhofer O, Brabletz S, Brabletz T. E-cadherin, β-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev. 2009;28(1–2):151–66.CrossRefPubMed Schmalhofer O, Brabletz S, Brabletz T. E-cadherin, β-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev. 2009;28(1–2):151–66.CrossRefPubMed
20.
Zurück zum Zitat Yang J, Mani SA, Donaher JL, et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell. 2004;117(7):927–39.CrossRefPubMed Yang J, Mani SA, Donaher JL, et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell. 2004;117(7):927–39.CrossRefPubMed
Metadaten
Titel
RNA interference against TMEM97 inhibits cell proliferation, migration, and invasion in glioma cells
verfasst von
Guanzhong Qiu
Wei Sun
Yongxiang Zou
Zheng Cai
Peng Wang
Xianbin Lin
Jinxiang Huang
Lei Jiang
Xuehua Ding
Guohan Hu
Publikationsdatum
01.10.2015
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 10/2015
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3552-6

Weitere Artikel der Ausgabe 10/2015

Tumor Biology 10/2015 Zur Ausgabe

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

03.05.2024 Mammakarzinom Nachrichten

Wenn bei Mammakarzinomen durch eine neoadjuvante Chemotherapie ein Downstaging von nodal-positiv zu nodal-negativ gelingt, scheint es auch ohne Axilladissektion nur selten zu axillären Rezidiven zu kommen.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

02.05.2024 Prostatakarzinom Nachrichten

Eine adjuvante Radiotherapie nach radikaler Prostata-Op. bringt den Betroffenen wahrscheinlich keinen Vorteil. Im Gegenteil: Durch die Bestrahlung steigt offenbar das Risiko für Harn- und Stuhlinkontinenz.

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärzte und Psychotherapeuten.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.